Dosing chart / Growth hormone
CJC-1295 (no DAC) vs CJC-1295 with DAC
Dose, schedule, route and approval status side by side.
Reference only, not medical advice. Doses marked FDA-approved come from the US prescribing label. Doses marked Not approved are ranges reported from small studies or community use and have not been established as safe or effective in humans. Check anything here with a licensed clinician before acting on it. Read the full disclaimer.
| CJC-1295 (no DAC) | CJC-1295 with DAC | |
|---|---|---|
| Status | Not approved | Not approved |
| Also known as | Mod GRF 1-29 | DAC:GRF |
| Typical dose | 100 mcg | 1–2 mg |
| How often | Daily, 1–3 times | Weekly |
| Schedule | One to three times daily, often paired with a GHRP or ipamorelin. | Once weekly. |
| Daily equivalent | 100–300 mcg/day | ≈ 143–286 mcg/day |
| Route | Subcutaneous | Subcutaneous |
| Duration | 8–12 weeks reported | 8–12 weeks reported |
| Notes | Short-acting GHRH analog. No completed efficacy trials; doses are community-reported. | Long-acting form with a half-life of about a week. Clinical development stopped in Phase 2. |
This page sets the two chart entries next to each other. It does not say which is better or whether either is right for you. Read member experiences on the CJC-1295 (no DAC) and CJC-1295 with DAC pages.
Advertisement